Literature DB >> 8441412

Differential pp40I kappa B-beta inhibition of DNA binding by rel proteins.

J A Diehl1, T A McKinsey, M Hannink.   

Abstract

Regulation of gene expression by members of the NF-kappa B/rel transcription factor family is a central component of signal transduction pathways utilized by many cellular processes, including lymphocyte activation, embryonic development, and oncogenesis. The members of the NF-kappa B/rel transcription factor family are regulated by association with a family of inhibitor (I kappa B) proteins (I kappa B) proteins. To address the importance of the association between rel and I kappa B proteins for oncogenesis by rel proteins, we characterized rel-I kappa B interactions in chicken embryo fibroblasts (CEF) infected with retroviral vectors encoding the avian c-rel (p68c-rel), v-rel (p59v-rel), and I kappa B-beta (pp40I kappa B-beta) proteins. In these experiments, the p59v-rel:pp40I kappa B-beta ratio in coinfected CEF was nearly identical to the p59v-rel:pp40I kappa B-beta ratio in v-rel-transformed cells. The avian I kappa B-beta protein, pp40I kappa B-beta, was able to associate with both the nononcogenic p68c-rel and the oncogenic p59v-rel. Association of p68c-rel with pp40I kappa B-beta in coinfected CEF resulted in inhibition of the DNA-binding activity of p68c-rel. Anti-pp40I kappa B-beta serum was able to restore DNA binding to p68c-rel in the presence of high levels of pp40I kappa B-beta, indicating that pp40I kappa B-beta functions in a trans-acting manner to inhibit DNA binding by p68c-rel. In contrast, sequence-specific DNA binding by the oncogenic v-rel protein, p59v-rel, was not abolished by pp40I kappa B-beta in coinfected CEF. Anti-pp40I kappa B-beta serum did not immunoprecipitate the p59v-rel-DNA adduct or alter the electrophoretic mobility of the p59v-rel-DNA adduct, consistent with the idea that pp40I kappa B-beta and DNA are competitive inhibitors for the same or overlapping domains on rel proteins. Internal v-rel-derived sequences were identified that are responsible for loss of pp40I kappa B-beta-mediated inhibition of DNA binding by p59v-rel. Loss of pp40I kappa B-beta-mediated inhibition of DNA binding by recombinant v/c-rel proteins was not sufficient for oncogenic activation of c-rel. Instead, removal of C-terminal c-rel-derived sequences in addition to loss of pp40I kappa B-beta-mediated inhibition of DNA binding was required for oncogenic activation of c-rel. These results demonstrate the presence of an interaction between internal and C-terminal regions of the c-rel protein that is important for the ability of c-rel to regulate the proliferation of lymphoid cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8441412      PMCID: PMC359489          DOI: 10.1128/mcb.13.3.1769-1778.1993

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  43 in total

1.  Cloning of a mitogen-inducible gene encoding a kappa B DNA-binding protein with homology to the rel oncogene and to cell-cycle motifs.

Authors:  V Bours; J Villalobos; P R Burd; K Kelly; U Siebenlist
Journal:  Nature       Date:  1990-11-01       Impact factor: 49.962

2.  The DNA binding subunit of NF-kappa B is identical to factor KBF1 and homologous to the rel oncogene product.

Authors:  M Kieran; V Blank; F Logeat; J Vandekerckhove; F Lottspeich; O Le Bail; M B Urban; P Kourilsky; P A Baeuerle; A Israël
Journal:  Cell       Date:  1990-09-07       Impact factor: 41.582

3.  Isolation of a rel-related human cDNA that potentially encodes the 65-kD subunit of NF-kappa B.

Authors:  S M Ruben; P J Dillon; R Schreck; T Henkel; C H Chen; M Maher; P A Baeuerle; C A Rosen
Journal:  Science       Date:  1991-03-22       Impact factor: 47.728

4.  c-rel activates but v-rel suppresses transcription from kappa B sites.

Authors:  J Inoue; L D Kerr; L J Ransone; E Bengal; T Hunter; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

5.  Interaction of the v-rel protein with an NF-kappa B DNA binding site.

Authors:  N Kabrun; J W Hodgson; M Doemer; G Mak; B R Franza; P J Enrietto
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-01       Impact factor: 11.205

6.  vRel is an inactive member of the Rel family of transcriptional activating proteins.

Authors:  P M Richardson; T D Gilmore
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

7.  The mouse c-rel protein has an N-terminal regulatory domain and a C-terminal transcriptional transactivation domain.

Authors:  P Bull; K L Morley; M F Hoekstra; T Hunter; I M Verma
Journal:  Mol Cell Biol       Date:  1990-10       Impact factor: 4.272

8.  DNA binding and I kappa B inhibition of the cloned p65 subunit of NF-kappa B, a rel-related polypeptide.

Authors:  G P Nolan; S Ghosh; H C Liou; P Tempst; D Baltimore
Journal:  Cell       Date:  1991-03-08       Impact factor: 41.582

9.  Characterization of an immediate-early gene induced in adherent monocytes that encodes I kappa B-like activity.

Authors:  S Haskill; A A Beg; S M Tompkins; J S Morris; A D Yurochko; A Sampson-Johannes; K Mondal; P Ralph; A S Baldwin
Journal:  Cell       Date:  1991-06-28       Impact factor: 41.582

10.  Cloning of the DNA-binding subunit of human nuclear factor kappa B: the level of its mRNA is strongly regulated by phorbol ester or tumor necrosis factor alpha.

Authors:  R Meyer; E N Hatada; H P Hohmann; M Haiker; C Bartsch; U Röthlisberger; H W Lahm; E J Schlaeger; A P van Loon; C Scheidereit
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-01       Impact factor: 11.205

View more
  17 in total

1.  Mutational analysis of the v-Rel dimerization interface reveals a critical role for v-Rel homodimers in transformation.

Authors:  Andrew S Liss; Henry R Bose
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

2.  Loss of IkappaB alpha-mediated control over nuclear import and DNA binding enables oncogenic activation of c-Rel.

Authors:  S Sachdev; M Hannink
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

3.  Differential regulation of the inhibitor of apoptosis ch-IAP1 by v-rel and the proto-oncogene c-rel.

Authors:  Jarmila Kralova; Andrew S Liss; William Bargmann; Cullen Pendleton; Janani Varadarajan; Emin Ulug; Henry R Bose
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

4.  I kappa B alpha-mediated inhibition of v-Rel DNA binding requires direct interaction with the RXXRXRXXC Rel/kappa B DNA-binding motif.

Authors:  S Kumar; C Gélinas
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

5.  Heterologous C-terminal sequences disrupt transcriptional activation and oncogenesis by p59v-rel.

Authors:  J A Diehl; M Hannink
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

6.  Identification of a C/EBP-Rel complex in avian lymphoid cells.

Authors:  J A Diehl; M Hannink
Journal:  Mol Cell Biol       Date:  1994-10       Impact factor: 4.272

7.  Evolution of the oncogenic potential of v-rel: rel-induced expression of immunoregulatory receptors correlates with tumor development and in vitro transformation.

Authors:  J Nehyba; R Hrdlicková; E H Humphries
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

8.  Transformation of avian fibroblasts overexpressing the c-rel proto-oncogene and a variant of c-rel lacking 40 C-terminal amino acids.

Authors:  J Kralova; J D Schatzle; W Bargmann; H R Bose
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

9.  The reverse two-hybrid system: a genetic scheme for selection against specific protein/protein interactions.

Authors:  C A Leanna; M Hannink
Journal:  Nucleic Acids Res       Date:  1996-09-01       Impact factor: 16.971

10.  PEST-dependent cytoplasmic retention of v-Rel by I(kappa)B-alpha: evidence that I(kappa)B-alpha regulates cellular localization of c-Rel and v-Rel by distinct mechanisms.

Authors:  E M Rottjakob; S Sachdev; C A Leanna; T A McKinsey; M Hannink
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.